Glycolysis-enhancing drugs like terazosin were associated with slower progression of cognitive dysfunction and lower risks of developing Alzheimer's disease.
Observational
Do terazosin and other glycolysis-enhancing drugs reduce the risk and progression of Alzheimer's disease?
Terazosin and other glycolysis-enhancing α1-adrenergic antagonists demonstrate neuroprotective potential and may reduce the risk and progression of Alzheimer's disease across experimental models and human cohorts.
Abstract Background Terazosin (TZ) is widely prescribed for hypertension and benign prostatic hyperplasia. Recent studies suggest that TZ enhances glycolysis and may protect against neurodegenerative diseases. Methods We tested the hypothesis that TZ is neuroprotective in Alzheimer’s disease (AD) in a yeast model, a mouse model, and two human datasets. Results We report four main results. First, TZ increased ATP levels in a Saccharomyces cerevisiae mutant with impaired metabolism, and reduced Amyloid-beta42 (Aβ42) aggregation. Second, in 5xFAD mice, TZ attenuated amyloid pathology and rescued cognitive impairments in spatial memory and interval timing. Third, in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database, AD patients taking glycolysis-enhancing drugs had a slower progression of both cognitive dysfunction and metabolic neuroimaging biomarkers (18 F-fluorodeoxyglucose positron emission tomography (FDG-PET)). Finally, in the Merative Marketscan dataset, patients taking glycolysis-enhancing drugs had lower risks of developing AD. Conclusion These data provide preliminary evidence that glycolysis-enhancing drugs have therapeutic potential in AD.
Zhang et al. (Thu,) conducted a observational in Alzheimer's disease. Glycolysis-enhancing drugs (Terazosin) was evaluated on Progression of cognitive dysfunction, metabolic neuroimaging biomarkers, and risk of developing Alzheimer's disease. Glycolysis-enhancing drugs like terazosin were associated with slower progression of cognitive dysfunction and lower risks of developing Alzheimer's disease.